Company intelligence / Profile preview

Medinet

Ownership: Private
Employees: ~92
Development stage: Commercial

Overview

Medinet is a leading Japanese CDMO specializing in regenerative medicine and cell therapy. It has commercialized immune cell therapy technology since 1999 and provides comprehensive support from pre-clinical research through to commercial launch. Its GDT cell technology has been used in over 50 medical institutions since 2007 and advanced into Phase II/III clinical trials.

Therapeutic areas: OncologyImmunology
Modalities: Cell therapyRegenerative medicine products
Industry: Contract Manufacturing Organization

Partnerships

University of Tokyo Hospital ("Department of Immunotherapeutics" at the University’s Medical Center)National Hospital Organization Osaka Medical CenterKyushu University's Center for Advanced Medical Innovation

Beyond the preview

Go deeper on Medinet.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medinet.

Explore the full profile